المؤلفون: De Greef, Axel, Ghislain, Pierre-Dominique, de Montjoye, Laurence, Baeck, Marie

المساهمون: UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie

المصدر: Advances in Therapy, Vol. 40, no.5, p. 2509-2514 (2023)

مصطلحات موضوعية: Pharmacology (medical), General Medicine

الوصف: Introduction: The efficacy and safety of upadacitinib in atopic dermatitis have been defined in clinical trials, but long-term real-life experience, essential for clinical decision-making, is still limited. We aimed to assess the effectiveness and tolerance of upadacitinib in a real-life cohort of adults and adolescents with severe atopic dermatitis in whom previous systemic therapies largely failed. Methods: Retrospective cohort study collecting data from adults and adolescents treated with upadacitinib 15 or 30 mg per day between July 2021 to August 2022. The outcomes for effectiveness were evaluated by the percentage of patients who achieved a validated Investigator's Global Assessment for atopic dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and/or an improvement of at least 75% on the Eczema Area and Severity Index (EASI 75) at the end of the follow-up. All treatment-emergent adverse events were collected. Results: A total of 29 patients were included (22 adults and 7 adolescents), with a median follow-up of 54.4 weeks. At the end of the follow-up, 23 patients (79.3%) reached a vIGA-AD of 0/1, and 24 patients (82.7%) achieved EASI 75. Among patients treated with upadacitinib after initial failure of first- and/or second-line treatment with biologics or baricitinib, 5/7 patients (71.4%) reached a vIGA-AD score of 0/1. Disease control was slightly better in adults than in adolescents (81.8% vs 71.4% reached the efficacy endpoint, respectively). Response rate in patients with upadacitinib 15 mg seemed better than in clinical trials or network meta-analysis. Safety data were reassuring; lipid changes were the most frequent adverse event. Conclusion: This real-life study confirms the effectiveness of upadacitinib, particularly for the treatment of atopic dermatitis recalcitrant to conventional systemic agents, biologics or baricitinib. Induced lipid changes require close follow-up.

العلاقة: boreal:278591; http://hdl.handle.net/2078.1/278591Test; urn:ISSN:0741-238X; urn:EISSN:1865-8652

الإتاحة: https://doi.org/10.1007/s12325-023-02490-5Test
http://hdl.handle.net/2078.1/278591Test

المؤلفون: De Greef, Axel, Ghislain, Pierre-Dominique, de Montjoye, Laurence, Baeck, Marie

المساهمون: UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de dermatologie

المصدر: Advances in Therapy, Vol. 40, no.5, p. 2509-2514 (2023)

مصطلحات موضوعية: Pharmacology (medical), General Medicine

الوصف: Introduction: The efficacy and safety of upadacitinib in atopic dermatitis have been defined in clinical trials, but long-term real-life experience, essential for clinical decision-making, is still limited. We aimed to assess the effectiveness and tolerance of upadacitinib in a real-life cohort of adults and adolescents with severe atopic dermatitis in whom previous systemic therapies largely failed. Methods: Retrospective cohort study collecting data from adults and adolescents treated with upadacitinib 15 or 30 mg per day between July 2021 to August 2022. The outcomes for effectiveness were evaluated by the percentage of patients who achieved a validated Investigator's Global Assessment for atopic dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and/or an improvement of at least 75% on the Eczema Area and Severity Index (EASI 75) at the end of the follow-up. All treatment-emergent adverse events were collected. Results: A total of 29 patients were included (22 adults and 7 adolescents), with a median follow-up of 54.4 weeks. At the end of the follow-up, 23 patients (79.3%) reached a vIGA-AD of 0/1, and 24 patients (82.7%) achieved EASI 75. Among patients treated with upadacitinib after initial failure of first- and/or second-line treatment with biologics or baricitinib, 5/7 patients (71.4%) reached a vIGA-AD score of 0/1. Disease control was slightly better in adults than in adolescents (81.8% vs 71.4% reached the efficacy endpoint, respectively). Response rate in patients with upadacitinib 15 mg seemed better than in clinical trials or network meta-analysis. Safety data were reassuring; lipid changes were the most frequent adverse event. Conclusion: This real-life study confirms the effectiveness of upadacitinib, particularly for the treatment of atopic dermatitis recalcitrant to conventional systemic agents, biologics or baricitinib. Induced lipid changes require close follow-up.

العلاقة: boreal:278591; http://hdl.handle.net/2078.1/278591Test; urn:ISSN:0741-238X; urn:EISSN:1865-8652

الإتاحة: https://doi.org/10.1007/s12325-023-02490-5Test
http://hdl.handle.net/2078.1/278591Test

المؤلفون: De Greef, Axel, Ghislain, Pierre-Dominique, de Montjoye, Laurence, Baeck, Marie

المصدر: Advances in Therapy ; volume 40, issue 5, page 2509-2514 ; ISSN 0741-238X 1865-8652

مصطلحات موضوعية: Pharmacology (medical), General Medicine

الإتاحة: https://doi.org/10.1007/s12325-023-02490-5Test

المؤلفون: De Greef, Axel, Ghislain, Pierre-Dominique, Bulinckx, Audrey, Coster, Alison, de Halleux, Céline, Damsin, Thomas, Jacobs, Marie-Claude, Suys, Erwin, Zoghaib, Samer, Baeck, Marie

المصدر: Clinical Drug Investigation ; volume 43, issue 4, page 299-306 ; ISSN 1173-2563 1179-1918

مصطلحات موضوعية: Pharmacology (medical), General Medicine

الإتاحة: https://doi.org/10.1007/s40261-023-01258-7Test